Glycomic approaches toward drug development: Therapeutically exploring the glycosaminoglyconome

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 6, 2006, Pages 521-528

  Gesslbauer, Bernd ^a   Kungl, Andreas J ^a,b  

^a UNIVERSITY OF GRAZ   (Austria)

^b ProtAffin Biotechnologie AG   (Austria)

Author keywords

Chemokine; FGF; Heparan sulfate; Inflammation; Mass spectrometry

Indexed keywords

ANTIINFLAMMATORY AGENT; ARANESEP; CHEMOKINE; CHONDROITIN SULFATE; DALTEPARIN; DERMATAN SULFATE; ENOXAPARIN; ERYTHROPOIETIN; FONDAPARINUX; GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCANOME; HEPARAN SULFATE; HEPARIN; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; KERATAN SULFATE; LOW MOLECULAR WEIGHT HEPARIN; PA 04 001; PENTASACCHARIDE; RECOMBINANT ERYTHROPOIETIN; TINZAPARIN;

AMINO ACID SEQUENCE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; CAPILLARY ELECTROPHORESIS; CARBOHYDRATE ANALYSIS; CELL ACTIVATION; CELL MIGRATION; CHEMICAL STRUCTURE; CHROMATOGRAPHY; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ELECTRICITY; GEL ELECTROPHORESIS; GENOMICS; GLYCOBIOLOGY; HOST RESISTANCE; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MASS SPECTROMETRY; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEOMICS; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

CARBOHYDRATE SEQUENCE; DRUG DESIGN; GLYCOSAMINOGLYCANS; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN BINDING; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 33845521471     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Yip GW, Smollich M, Gotta M: Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther (2008) 5(9):2139-2148.
2. Ohtsubo K, Marth JD: Glycosylation in cellular mechanisms of health and disease. Cell (2008) 126(5):855-867.
3. Taylor KR, Gallo RL: Glycosaminoglycans and their proteoglycans: Host-associated molecular patterns for initiation and modulation of inflammation. FASEB J (2008) 20(1):9-22.
4. Rose MJ, Page C: Glycosaminoglycans and the regulation of allergic inflammation. Curr Drug Targets Inflamm Allergy (2004) 3:221-225.
5. Coutinho PM, Deleury E, Davies GJ, Henrissat B: An evolving hierarchical family classification for glycosyltransferases. J Mol Biol (2003) 328(2):307-317.
6. Cattaruzza S, Perris R: Approaching the proteoglycome: Molecular interactions of proteoglycans and their functional output. Macromol Biosci (2006) 6(8):667-680.
7. Wu ZL, Zhang L, Yabe T, Kuberan B, Beeler DL, Love A, Rosenberg RD: The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex. J Biol Chem (2003) 278(19):17121-17129.
8. Stowers AW, Chen LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH: A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci USA (2002) 99(1):339-344.
9. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoletin antibodies in patients treated with recombinant erythropoletin. N Engl J Med (2002) 346(7):469-475.
10. Gemgross TU: Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol (2004) 22(11):1409-1414. Erratum in: Nat Biotechnol (2004) 22(12):1589.
11. Zhang C, Griffith BR, Fu Q, Albermann C, Fu X, Lee IK, Li L, Thorson JS: Exploiting the reversibility of natural product glycosyltransferase-catalyzed reactions. Science (2006) 316(5791):1291-1294.
12. Vervecken W, Kaigorodov V, Callewaert N, Geysens S, De Vusser K, Contreras R: In vivo synthesis of mammallan-like, hybrid-type N-glycans in Pichia pastoris. Appl Environ Microbiol (2004) 70(5):2639-2646.
13. Prati EG, Matasci M, Suter TB, Dinter A, Sburlati AR, Bailey JE: Engineering of coordinated up- and down-regulation of two glycosyltransferases of the O-glycosylation pathway in Chinese hamster ovary (CHO) cells. Biotechnol Bioeng (2002) 79(5):580-585.
14. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA: Darbepoetin α has a longer circulating half-life and greater in vivo potency than recombinant human erythropoletin. Exp Hematol (2003) 31(4):290-299.
15. Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, Ponting I: Control of rHuEPO biological activity: The role of carbohydrate. Exp Hematol (2004) 32(12):1146-1155.
16. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hemday N et al: Enhancement of therapeutic protein in vivo activities through glycoongineering. Nat Biotechnol (2003) 21(4):414-421.
17. Plante OJ, Seeberger PH: Recent advances in automated solid-phase carbohydrate synthesis: From screening to vaccines. Curr Opin Drug Discov Dev (2003) 6(4):521-525.
18. Seeberger PH, Werz DB: Automated synthesis of oligosaccharides as a basis for drug discovery. Nat Rev Drug Discov (2005) 4(9):751-763.
19. Hiller E: Cancer and thrombosis: Managing the risks and approaches to thromboprophylaxis. Onkologie (2008) 29(10):474-478.
20. Bates SM, Weitz JI: The status of new anticoagulants. Br J Heematol (2006) 134(1):3-19.
21. Petitou M, van Boeckel CA: A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew Chem Int Ed Engl (2004) 43(24):3118-3133.
22. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood (1993) 82(11):3253-3258.
23. Wang L, Brown JR, Varki A, Esko JD: Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest (2002) 110(1):127-136.
24. Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, Bibby M, Double J, Craig S, Leeming D, Stevenson K et al: Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res (2005) 11(22):8172-8179.
25. Stevenson JL, Choi SH, Varki A: Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res (2005) 11(19 Pt 1):7003-7011.
26. Naggi A, Casu B, Perez M, Torri G, Cassineill G, Penco S, Pisano C, Giannini G, Ishal-Michaeli R, Viodavsky I: Modulation of the heparanase-inhibiting activity of haparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem (2005) 280(13):12103-12113.
27. Ma Q, Schultz C, Neville B, Jeske W, Hoppensteadt D, Cornelli U, Lee J, Lorens S, Hanin I, Fareed J: Pharmacodynamics and pharmacokinetics of C3, a heparin-derived ollgosaccharide mixture, in non-human primates. Thromb Res (2003) 112(4):249-255.
28. Beauhamols ME, Lindquist KC, Marathe D, Vanderslice P, Xia J, Matta KL, Neelamegham S: Affinity and kinetics of sialyl Lewis-X and core-2 based oligosaccharides binding to L- and P-selectin. Biochemistry (2005) 44(27):9507-9519.
29. Petitou M, Lormeau JC, Choay J: Interaction of heparin and antithrombin III. The role of O-sulfate groups. Eur J Biochem (1988) 176(3):637-640.
30. Petitou M, Lormeau JC, Choay J: A now synthetic pentasaccharide with increased anti-Factor Xa activity. Possible role for anionic clusters in the interaction of heparin and antithrombin III. Semin Thromb Hemost (1991) 17(Suppl 2):143-146.
31. Rahmoune H, Chen HL, Gallagher JT, Rudland PS, Femig DG: Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. J Biol Chem (1998) 273(13):7303-7310.
32. Robinson CJ, Harmer NJ, Goodger SJ, Blundell TL, Gallagher JT: Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2.2.1 FGF1.FGFR2c.heparin ternary complexes. J Biol Chem (2005) 280(51):42274-42282.
33. Sanderson RD: Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol (2001) 12(2):89-98.
34. Kjellen L: Glucosaminyl N-deacetylase/N-sulphotransferases in heparan sulphate biosynthesis and biology. Biochem Soc Trans (2003) 31(2):340-342.
35. Lensen JF, Rops AL, Wijnhoven TJ, Hafmans T, Feltz WF, Oosterwijk E, Banas B, Bindels RJ, van den Heuvel LP, van der Viag J, Berden JH, van Kuppevelt TH: Localization and functional characterization of glycosaminoglycan domains in the normal human kidney as revealed by phage display-derived single chain antibodies. J Am Soc Nephrol (2005) 16(5):1279-1288.
36. Hardy LA, Booth TA, Lau EK, Handel TM, Ali S, Kirby JA: Examination of MCP-1 (CCL2) partitioning and presentation during transendothellal leukocyte migration. Lab Invest (2004) 84(1):81-90.
37. Cardin AD, Weintraub HJ: Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis (1989) 9(1):21-32.
38. Hileman RE, Fromm JR, Weller JM, Linhardt RJ: Glycosaminoglycan-protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins. Bioessays (1998) 20(2):156-167.
39. Kuschert GS, Hoogewerf AJ, Proudfoot AE, Chung CW, Cooke RM, Hubbard RE, Wells TN, Sanderson PN: Identification of a glycosaminoglycan binding surface on human interleukin-8. Biochemistry (1998) 37(32):11193-11201.
40. Habuchi H, Habuchi O, Kimata K: Sulfation pattern in glycosaminoglycan: Does it have a code? Glycoconj J (2004) 21(1-2):47-52.
41. Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J: Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry (1987) 26(20):6454-6461.
42. Jemth P, Kreuger J, Kusche-Gullberg M, Sturiale L, Gimenez-Gallego G, Lindahl U: Biosynthetic oligosaccharide libraries for identification of protein-binding heparan sulfate motifs. Exploring the structural diversity by screening for fibroblast growth factor (FGF)1 and FGF2 binding. J Biol Chem (2002) 277(34):30567-30573.
43. Ashikari-Hada S, Habuchi H, Kanya Y, Itoh N, Reddi AH, Kimata K: Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem (2004) 279(13):12346-12354.
44. Lindahl U, Backstrom G, Thunberg L, Leder IG: Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA (1980) 77(11):6551-6555.
45. Tyrrell DJ, Ishihara M, Rao N, Home A, Kiefer MC, Stauber GB, Lam LH, Stack RJ: Structure and biological activities of a haparin-derived hexasaccharide with high affinity for basic fibroblast growth factor. J Biol Chem (1993) 268(7):4684-4689.
46. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC: Heparin structure and interactions with basic fibroblast growth factor. Science (1996) 271(5252):1116-1120.
47. Liu J, Shriver Z, Pope RM, Thorp SC, Duncan MB, Copeland RJ, Raska CS, Yoshida K, Eisenberg RJ, Cohen G, Linhardt RJ, Sasisekharan R: Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem (2002) 277(38):33456-33467.
48. Tumbull JE, Femig DG, Ke Y, Wilkinson MC, Gallagher JT: Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem (1992) 267(15):10337-10341.
49. Kreuger J, Matsumoto T, Vanwildemeersch M, Sasaki T, Timpl R, Claesson-Weish L, Spillmann D, Lindahl U: Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J (2002) 21(23):6303-6311.
50. Spillmann D, Witt D, Lindahl U: Defining the interleukin-8-binding domain of heparan sulfate. J Biol Chem (1998) 273(25):15487-15493.
51. Ostrovsky O, Berman B, Gallagher J, Mulloy B, Femig DG, Delehedde M, Ron D: Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J Biol Chem (2002) 277(4):2444-2453.
52. Yu Y, Sweeney MD, Saad OM, Crown SE, Hsu AR, Handel TM, Leary JA: Chemokine-glycosaminoglycan binding: Specificity for CCR2 ligand binding to highly sulfated oligosaccharides using FTICR mass spectrometry. J Biol Chem (2005) 280(37):32200-32208.
53. Yu Y, Sweeney MD, Saad OM, Leary JA: Potential inhibitors of chemokine function: Analysis of noncovalent complexes of CC chemokine and small polyanionic molecules by ESI FT-ICR mass spectrometry. J Am Soc Mass Spectrom (2006) 17(4):524-535.
54. Saad OM, Myers RA, Castleton DL, Leary JA: Analysis of hyaluronan content in chondroitin sulfate preparations by using selective enzymatic digestion and electrospray ionization mass spectrometry. Anal Biochem (2005) 344(2):232-239.
55. Zamfir A, Seidler DG, Schonherr E, Kresse H, Peter-Katallnic J: On-line sheathless capillary electrophoresis/nanoelectrospray ionization-tandem mass spectrometry for the analysis of glycosaminoglycan oligosaccharides. Electrophoresis (2004) 26(13):2010-2016.
56. Shriver Z, Raman R, Venkataraman G, Drummond K, Turnbull J, Tolda T, Linhardt R, Biemann K, Sasisekharan R: Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site. Proc Natl Acad Sci USA (2000) 97(19):10359-10364.
57. Naggar EF, Costello CE, Zaia J: Competing fragmentation processes in tandem mass spectra of heparin-like glycosaminoglycans. J Am Soc Mass Spectrom (2004) 15(11):1534-1544.
58. Zamfir A, Seidler DG, Kresse H, Peter-Katalinic J: Structural investigation of chondroitin/dermatan sulfate oligosaccharides from human skin fibroblast decorin. Glycobiology (2003) 13(11):733-742.
59. Zamfir A, Seidler DG, Kresse H, Peter-Katalinic J: Structural characterization of chondroitin/dermatan sulfate oligosaccharides from bovine aorta by capillary electrophoresis and electrospray ionization quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom (2002) 16(21):2015-2024.
60. Zamfir A, Vakhrushev S, Sterling A, Niebel HJ, Allen M, Peter-Katalinic J: Fully automated chip-based mass spectrometry for complex carbohydrate system analysis. Anal Chem (2004) 76(7):2046-2054.
61. Potzinger H, Geretti E, Brandner B, Wabitsch V, Piccinini AM, Rek A, Kungi AJ: Developing chemokine mutants with improved proteoglycan affinity and knocked-out GPCR activity as anti-inflammatory recombinant drugs. Biochem Soc Trans (2006) 34(3):435-437.